鷺燕醫藥(002788.SZ)調整公司2019年度配股方案決議有效期
格隆匯12月11日丨鷺燕醫藥(002788.SZ)公佈,公司於2019年12月11日召開第四屆董事會第十七次會議、第四屆監事會第十四次會議,審議通過《關於調整公司2019年度配股公開發行證券方案決議有效期的議案》,公司董事會同意提請股東大會對公司本次配股方案決議有效期進行調整,將本次配股方案相關決議有效期由“本次配股的決議自公司股東大會審議通過之日起12 個月內有效。如果公司已於該有效期內取得證監會關於本次配股的核準文件但未能實施完畢,則決議有效期自動延長至本次配股實施完成日。如國家法律、法規對上市公司配股有新的規定,公司按照新的規定對公司配股方案進行調整”調整為“本次配股的決議自公司2019年第2次臨時股東大會審議通過之日起12 個月內有效”。
上述調整事項尚需提交公司股東大會審議通過。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.